ArticleArthritis research & therapy2025
Clinical significance of inflammation-coagulation-autoantibody triad in systemic sclerosis-associated interstitial lung disease: a retrospective study.
Article in Arthritis research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- The clinical and translational perspectives on the lung microbiome in interstitial lung diseases: a bibliometric review.Journal of thoracic disease · 2026Article
- Immunological coagulation dual axis stratification identifies ultra high-risk phenotypes in systemic sclerosis.Frontiers in immunology · 2026Article
- Biomarker patterns across skin-lung-gut burden in systemic sclerosis.Frontiers in immunology · 2026Article
- Predictive Value of Perioperative Systemic Inflammation Response Index Dynamics for Postoperative Pulmonary Infection Following Esophagectomy: A Multicenter Retrospective Cohort Study.Journal of inflammation research · 2026Article
- Integrated inflammatory-immune-nutritional signatures differentiate lung phenotypes in systemic sclerosis.Frontiers in medicine · 2026Article
- Diagnostic utility of erythrocyte sedimentation rate and anti-Scl-70 positivity for interstitial lung disease in diffuse systemic sclerosis.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundInterstitial lung disease (ILD) is highly prevalent among systemic sclerosis (SSc) patients and is the leading cause of mortality. This study aims to evaluate the independent and combined value of inflammatory markers, coagulation parameters, and autoantibodies for the presence of SSc-ILD.
methodsA total of 177 patients with SSc were enrolled in this study, including 116 patients with SSc-ILD and 61 without ILD. Multivariate logistic regression was performed to identify independently associated factors for SSc-ILD. The identification efficiency of individual and combined biomarkers was assessed using receiver operating characteristic curves, with the DeLong test applied to compare differences in area under the curve.
resultsThe incidence of dcSSc, Raynaud's phenomenon, and digestive system involvement was significantly higher in the SSc-ILD group. Four stepwise models were constructed, and the results of the full-factor model indicated that elevated NLR (neutrophil to lymphocyte ratio), prolonged PT (prothrombin time), and anti-SCL-70 antibody positivity were independent associated factors for SSc-ILD. The combined model of NLR, PT, and anti-SCL-70 yielded an AUC of 0.879 (95% CI: 0.828-0.930), which was significantly greater than any individual marker (P < 0.001), with a sensitivity of 82.6% and a specificity of 85.0%.
conclusionNLR, PT, and anti-SCL-70 antibody together form a triad of independent associated factors for SSc-ILD, demonstrating substantial discriminatory potential when considered as a composite indicator.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.